Malta - English - Medicines Authority

macarthys laboratories limited bampton road, harold hill, romford essex, rm3 8ug, united kingdom - bismuth subnitrate, iodoform, liquid paraffin - impregnated dressing - bismuth subnitrate 20 % (w/w) iodoform 40 % (w/w) liquid paraffin 40 % (w/w) - medicated dressings

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - bismuth subcitrate potassium (unii: r3o80h60kx) (bismuth - unii:u015tt5i8h), metronidazole (unii: 140qmo216e) (metronidazole - unii:140qmo216e), tetracycline hydrochloride (unii: p6r62377kv) (tetracycline - unii:f8vb5m810t) - bismuth subcitrate potassium 140 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of pylera and other antibacterial drugs, pylera should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. pylera in combination with omeprazole are indicated for the treatment of patients with helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate h. pylori . the eradication of helicobacter pylori has been shown to reduce the risk of duodenal ulcer recurrence. do not administer methoxyflurane to patients taking pylera. the concurrent use of tetracycline hydrochloride, a component of pylera, with methoxyflurane has been reported to resu

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية ابن رشد - ibn rushd drug store - colloidal bismuth subcitrate calculated as bi2o3 , 120 mg - calculated as bi2o3 , 120 mg

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - bismuth subcitrate 304.6mg (approx. equivalent to 120mg bismuth trioxide.) - tablet - 120 mg - active: bismuth subcitrate 304.6mg (approx. equivalent to 120mg bismuth trioxide.) excipient: hypromellose macrogol 6000   magnesium stearate maize starch polacrilin potassium povidone

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - bismuth subcitrate 24 mg/ml - oral solution - 120mg/5ml - active: bismuth subcitrate 24 mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

beckman coulter australia pty ltd - ct833 - clinical chemistry substrate ivds - clinical chemistry reagent/substrate, when used in conjunction with beckman coulter analysers, calibrators and controls, is intended for the quantitative determination of various analyte concentrations in human plasma, urine and cerebrospinal fluid (csf).

Australia - English - Department of Health (Therapeutic Goods Administration)

wincot pty ltd - ct833 - clinical chemistry substrate ivds - the easymate multi-function monitoring system is a clinical chemistry reagent/substrate, used in conjunction with the easymate analysers, calibrators and controls for the measurement of blood glucose. uric acid, cholesterol and haemoglobin in human capillary blood. this system is used for home-use and point-of-care environments.

United States - English - NLM (National Library of Medicine)

allergan, inc. - bismuth subcitrate potassium (unii: r3o80h60kx) (bismuth cation - unii:zs9cd1i8ye), metronidazole (unii: 140qmo216e) (metronidazole - unii:140qmo216e), tetracycline hydrochloride (unii: p6r62377kv) (tetracycline - unii:f8vb5m810t) - bismuth subcitrate potassium 140 mg - pylera in combination with omeprazole are indicated for the treatment of patients with  helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate h. pylori . the eradication of helicobacter pylori   has been shown to reduce the risk of duodenal ulcer recurrence. to reduce the development of drug-resistant bacteria and maintain the effectiveness of pylera and other antibacterial drugs, pylera should be used to treat only indicated infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. do not administer methoxyflurane to patients taking pylera. the concurrent use of tetracycline hydrochloride, a component of pylera, with methoxyflurane has been reported to res

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - bismuth subnitrate; iodoform - cutaneous paste - 252mg/1gram ; 503mg/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

martindale pharmaceuticals ltd - iodoform; bismuth subnitrate - cutaneous paste - 400mg/1gram ; 200mg/1gram